about
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications.Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study.Cellular players in angiogenesis during the course of systemic sclerosis.Angiogenic cytokines and growth factors in systemic sclerosis.Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosisImpaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features.Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.The role of IL-1β in the bone loss during rheumatic diseases.Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literatureMacitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centersIncreased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre StudyAngiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation?Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS.Methotrexate: an old new drug in autoimmune disease.Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease.Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies.Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphosInterstitial lung disease in systemic sclerosis: current and future treatment.Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers.H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease.A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis.Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study.Tocilizumab for the treatment of adult-onset Still's disease: results from a case series.The CD68(+)/H-ferritin(+) cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pBiologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study.Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation:Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis.Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy.H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome.Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset.Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients.Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare.The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist.Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis.Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma.Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population.
P50
Q30251741-F323C72D-0D8B-4FD3-B74B-CEB5826F0DB7Q33256082-EE76C27F-87B7-4179-963F-AF29565F9386Q33898530-7BD943EF-4BF1-4D3D-908B-504A0CFF38FCQ34183211-5D776D6A-B174-48A1-8F6C-1590E3D392C7Q34183304-9263519F-7B85-4B8A-8304-A0A55DAD203BQ34199111-CFC7FF3A-FBE6-4A1D-8A6F-17DBFBC3F1E4Q34389943-D5B23A1D-0B70-4F95-8196-F32FA4BCEB60Q35115790-00015EEA-A5C8-4075-A58E-E12B42F7CB12Q35540844-1E743511-62A0-4801-80BA-0F5402BEEE59Q35687532-FA2FB7D4-E9C3-41D4-BEBC-11D145981E69Q36051223-76E91BE7-113B-4632-AC5B-23D6277B13E4Q36208563-6118F05E-2619-450B-A154-CBAC9B650BF9Q36254129-EC01E084-5D17-408A-A9B4-0BE5ED4F4E18Q37872399-72DBBFAC-6D83-4672-9963-E4DA10059824Q38062772-C962D772-DA9F-4596-BB87-3D995302F4A5Q38103284-C583DA34-90F9-4DC3-A967-062CD52DC0A2Q38253237-AF9B6F78-B418-4F60-BF3B-6D048F0B3E56Q38323485-6F4335E5-AFCE-4D26-8907-B324BFDC89ECQ38354793-3C717DCF-A86F-4A35-BE12-AD2BC7BD0644Q38637780-6C4A72C8-F532-4EDA-8333-AA4C62CC90CBQ38657993-6E051F11-3B84-4055-A562-15C682130D55Q38773637-A77EC96A-E48E-45B4-AFEE-F3F16F7E7D57Q39355242-581837B8-6955-483D-9A1D-CEA8F4A2F0FDQ39673488-E55F0C5C-4C25-4454-9FF4-E24FA0D30DAAQ39955870-2897713C-FE15-422A-8F23-9B803731E7FFQ40073352-34F2486C-FE2F-41D7-9C81-63CBA7FCE594Q40235629-3E5BC630-3E68-44D6-8F51-DF1D2B9C2675Q40352271-A9044E30-69E9-49AA-A031-9D420973F89EQ40484547-6BE21D3B-42E6-4E87-9602-D3261E6D756AQ40815110-6C13DB75-263F-4412-B5DC-FF598ABD0879Q42416370-9707E724-920B-4B7E-A228-ED611EFAB20EQ43871288-9BA251F1-7638-418E-884F-6F3B8C5B6956Q47727637-158784B7-A373-4AB0-A97E-92473063F2AAQ48329917-6988A68A-809B-42F1-A91C-34FFF96189ACQ48340351-3ED88B8E-8DA9-4FD9-91A8-8CE952C90E7FQ50318004-B5093968-DA92-45A5-A74B-B75563E069AAQ50945605-DAE01A4D-C457-4A44-913F-73682D58E5E2Q51724806-EEBBB90E-0051-4091-9A78-68E1657479F2Q52841896-B30208C2-2ED9-478F-BA1E-A976D53A2FF9Q54421707-E0038034-0A65-4A34-BF2C-2E9E67D8457A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vasiliki Liakouli
@ast
Vasiliki Liakouli
@en
Vasiliki Liakouli
@es
Vasiliki Liakouli
@nl
Vasiliki Liakouli
@sl
type
label
Vasiliki Liakouli
@ast
Vasiliki Liakouli
@en
Vasiliki Liakouli
@es
Vasiliki Liakouli
@nl
Vasiliki Liakouli
@sl
prefLabel
Vasiliki Liakouli
@ast
Vasiliki Liakouli
@en
Vasiliki Liakouli
@es
Vasiliki Liakouli
@nl
Vasiliki Liakouli
@sl
P106
P1153
11738825500
P31
P496
0000-0002-7392-9334